Nadolol

纳多洛尔

Report date: 2025/05/15 20:00:08
NME

Base Information

Drug NameNadolol
Drug Alias NameNadololum奈羟心安纳多罗尔萘羟心安羟氢萘心安 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta adrenergic receptors antagonists
TargetsBeta adrenergic receptors
Therapy Area/IndicationsDiabetic macular oedemaSmoking CessationChest Pain +[12] 
Global Approved IndicationsHyperthyroidismHypertensionAngina Pectoris +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1979/12/10
Country/TerritoryUnited StatesThailand
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUs Worldmeds Holdings Llc
China Registration ClassN/A

Develop Information

Active CompaniesInvirsa Inc
Inactive CompaniesSandozUs Worldmeds Holdings LlcInvion Inc
Active IndicationsDiabetic macular oedemaDiabetic RetinopathyDry Eye Syndromes +[4] 
Inactive IndicationsSmoking CessationChest PainHyperthyroidism +[8] 

Other Information

ATC CodeC07AA12
Related LinksWikipediaDrugBankKEGG